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The tumor suppressor gene protein 53 (p53) plays a general role in cell cycle control, the initiation of 
apoptosis and in DNA repair. The human p53 gene is mutated and accumulated in more than 50% of 
cancers. Codon 72 exon 4 polymorphism (Arg72Pro) of the p53 gene has been implicated in cancer risk. 
This study was aimed at investigating the possible association between p53 Arg72Pro polymorphism 
and susceptibility to breast cancer among Iranian population. The p53 Arg72Pro genotypes were 
determined by polymerase chain reaction - restriction fragment length polymorphism (PCR-RFLP) 
analysis in 135 breast cancer cases and 150 controls. The PCR products were digested with BstU I 
restriction enzyme and the DNA fragments were then resolved by electrophoresis in 2% agarose gel. 
Out of the 135 breast cancer samples, 102 (75.55 %) samples were heterozygous (Arg/Pro), 27 (20%) 
samples homozygous for arginine (Arg/Arg) and 6 (4.45%) samples homozygous for proline (Pro/Pro). 
The frequencies of the three p53 genotypes; Arg/Pro, Arg/Arg and Pro/Pro in controls were 62, 24 and 
14%, respectively. Heterozygosity for Arg/Pro of p53 codon 72 is potentially one of the genetic risk 
factors for breast cancer. The p53 Arg72Pro polymorphism may be used as a stratification marker in 
screening individuals at a high risk of breast cancer. 
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INTRODUCTION 
 
Breast cancer is the most frequently encountered cancer 
in women throughout the world. Epidemiologic studies 
have suggested a number of risk factors, including 
genetic and environmental ones. The protein 53 (p53) 
tumor suppressor gene is the most involved genetic 
factor for breast cancer (Mabrouk et al., 2003). The gene 
for the tumor suppressor protein p53 occupies a central 
role in mediating cellular responses to DNA damage. Its 
activation results in either growth arrest in the G1 phase 
of the cell cycle or in apoptosis. The p53 gene contains a 
variety of polymorphisms and mutations (Zur Hausen, 
2002; Aoki et al., 2009). Mutations in the p53 gene are 
associated with more than 50%  of  human  cancers,  and  
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90% of them affect p53-DNA interactions, and result in a 
partial or complete loss of transactivation functions (Zubo 
et al., 2009).  
The p53 tumor suppressor gene, located on 
chromosome 17p13, is one of the most commonly 
mutated genes in all types of human cancer (He et al., 
2011; Chen et al., 2008). The p53 tumor suppressor gene 
is frequently mutated in many forms of human 
carcinomas. A common polymorphism occurs at codon 
72 of exon 4, with two alleles encoding either arginine 
(CGC) or proline (CCC). This p53 polymorphism is 
reportedly associated with cancer susceptibility. The 
distribution of the three genotypes (Arg/Arg, Arg/Pro and 
Pro/Pro) depends largely on the ethnic composition of the 
studied population (Omori et al., 2004). Recent studies 
showed the relation between p53 gene polymorphism 
with cancer of the stomach (Takeda et al., 2000), lung 
(Özbey  et  al.,  2011),  breast  (Pich  et  al.,  2000), ovary  
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Figure 1. Genotype analysis by digestion of the amplified product and RFLP; lanes 1 and 
2 are homozygote samples for Arg allele, lanes 3-4 are Arg/Pro heterozygote and lanes 6 
and 7 are Pro homozygote samples. Lane M, 100 bp DNA ladder (Fermentas). 
 
 
 
(Agorastos et al., 2004) and cervix (Jiang et al., 2010) 
among others in different parts of the world. In the 
present study, we examined the relation between the 
codon 72 polymorphism in p53 and the risk for breast 
tumorigenesis in Iranian patients. 
 
 
MATERIALS AND METHODS 
 
Sample collection and DNA extraction 
 
Genomic DNA was purified from blood samples of 135 cases of 
breast cancer and 150 controls by DNA extraction kit according to 
the manufacturer’s instructions. Samples were recruited from 
different hospitals of Isfahan (central part of Iran) during the period 
from February 2010 - October 2011. The isolated DNA was 
quantified by the agarose gel. 
 
 
Primer, polymerase chain reaction (PCR) assay and restriction 
fragment length polymorphism (RFLP) analysis 
 
PCR amplification was performed with two sets of primers: the outer 
oligonucleotide primers (forward: 5'-GCT CTT TTC ACC CAT CTA 
CAG -3'; reverse: 5'-TGA AGT CTC ATG GAA GCC AGC-3') and 
the inner oligonucleotide primers (forward: 5'-TCC CCC TTG CCG 
TCC CAA- 3'; reverse: 5'-CGT GCA AGT CAC AGA CTT-3') (Doosti 
et al., 2011).  
The target sequence was amplified in a 50 µL reaction volume 
containing of genomic DNA, 0.2 mM dNTPs, 1X Taq buffer, 2 mM 
MgCl2, 100 ng of each primer, and 1 unit of Taq DNA polymerase 
(Fermentas, Germany). The first round of PCR was carried out by 
applying a step-up program as follows: initial denaturation for 5 min 
at 94°C, followed by 30 cycles of 94°C for 1 min, 58°C for 1 min, 
and 72°C for 1 min, with a final extension for 5 min at 72°C. Two to 
5 μL from the first round amplicon was used as a template for the 
second round PCR with the identical PCR program by inner 
oligonucleotide primers. 
The BstU I restriction enzyme cuts within the sequence 
corresponding to the arginine codon (CGC) at position 72 to 
generate two visible fragments of 160 and 119 bp, leaving the 
proline allele uncut. A 20-μL of PCR product was digested overnight 
at 37°C in a 25 μL reaction volume containing 5 units of BstU I 
(Fermentas, Germany). After overnight digestion, the fragments 
were separated by electrophoresis on a 2% agarose gel and 
stained with ethidium bromide. Logistic regression analyses were 
used to adjust for possible confounding variables, and data were 
evaluated using the Pearson 
2
 tests. 
 
 
RESULTS 
 
Genotyping of the p53 codon 72 polymorphism was 
successful in 135 of 142 (95.07%) breast cancer cases 
and 150 of 158 (94.93 %) controls. Codon 72 arginine 
and proline alleles were investigated by PCR-based 
digestion analysis. The recognition site (CGCG) of the 
restriction enzyme was present only in the arginine-
encoding allele. Thus, the proline allele is identified by 
the presence of a single fragment of 279 bp, and the 
arginine allele by two fragments of 160 and 119 bp, 
respectively. Heterozygous samples displayed all three 
fragments (Figure 1). 
The frequency of the two alleles in breast cancer 
patients was compared with the frequency in the healthy 
control subjects. A significant difference in the genotype 
distribution was observed between the controls and 
patients with breast cancer. The distribution of the 
Arg/Arg, Arg/Pro and Pro/Pro genotypes in the control 
group was 36, 93 and 21 respectively. Allele frequencies 
in the control group were 0.55 for the Arg allele and 0.45 
for the Pro allele. Among the patients, the frequencies of 
the Arg and Pro allele were 0.57 and 0.43 respectively. 
The corresponding distribution of the Arg/Arg, Arg/Pro 
and Pro/Pro genotypes in the patients was 27, 102 and 6, 
respectively (Table 1). 
Our results indicate that individual heterozygous for the 
Arg allele has a higher risk of developing breast cancer 
than homozygotes and proline- homozygotes. A 
comparison of the genotype frequencies between breast 
cancer patients and normal controls confirmed the 
accumulation of Arg/Pro genotype in these patients 
(P<0.01). 
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Table 1. Genotype and allele frequencies of p53 in patients with breast cancer and controls. 
 
Codon 72 genotypes Breast cancer (n = 95.07%) Controls (n = 94.93%) P-value 
Arg/Arg 27 (20) 36 (24) <0.01 
Arg/Pro 102 (75.55) 93 (62) <0.02 
Pro/Pro 6 (4.45) 21 (14) >0.005 
Arg Alleles 57 55 >0.10 
Pro Alleles 43 45 <0.05 
 
 
 
DISCUSSION 
 
Although several studies have attempted to establish an 
eventual association between the polymorphism at codon 
72 and human carcinogenesis, the issue is still a matter 
of controversy. Interestingly, a polymorphism has been 
demonstrated at codon 72, where the proline is frequently 
replaced by an arginine. Both forms are morphologically 
wild-type and do not differ in their ability to bind to DNA in 
a sequence-specific manner. However, there are a 
number of differences between these p53 variants in their 
abilities to bind components of the transcriptional 
machinery, to activate transcription, to induce apoptosis, 
and to repress the transformation of primary cells 
(Thomas et al., 1999). It has been shown that the codon 
72 polymorphism (Arg-Pro polymorphism) of the common 
tumor suppressor p53 gene contributes to susceptibility 
to breast cancer. The Arg/Pro heterozygous genotype 
occurred more frequently in this cancer. The prevalence 
of the Arg/Pro genotype in breast cancer was higher than 
that of other genotypes.  
In this study, we examined the prevalence of p53 
codon 72 polymorphisms in a number of Iranian groups 
of breast cancer patients and controls. The prevalence of 
the Arg/Pro genotype in carcinoma cases was statistically 
different from that of the controls (75.55% versus 62%). 
Several studies have examined the role of the codon 72 
polymorphism in mutation of the p53 gene in cancer. 
Langerod et al. (2002) identified p53 mutations more 
commonly in breast cancer from Arg/Arg homozygotes 
(28.5%), than among Arg/Pro heterozygotes (21%) or 
Pro/Pro homozygotes (4%). However, no difference in 
p53 mutation frequency among codon 72 genotypes has 
been reported in colorectal or bladder cancer (Furihata et 
al., 2002). Several studies have also suggested that the 
codon 72 Arg allele is preferentially mutated and retained 
in Arg/Pro heterozygotes (Tada et al., 2001). These 
authors have suggested that the codon 72 Arg containing 
mutants may have a selective growth advantage 
influencing the ratio of Arg and Pro containing mutants in 
tumors. Another study also observed the prevalence of 
homozygosity for the p53 Arg allele and a strong 
association between the Arg/Arg genotype in breast 
cancer patients (Buyru et al., 2003). Recently, higher 
number of arg allele was observed in breast cancer 
patients when compared to the controls suggesting that 
the arg allele may be associated with predisposing  India  
women to breast cancer (Suresh et al., 2011). 
 
 
CONCLUSIONS 
 
In this study, the heterozygosity for Arg/Pro of p53 codon 
72 was associated with breast cancer. Heterozygosity for 
Arg/Pro of p53 Arg72Pro is potentially one of the genetic 
risk factors for breast cancer in Iranian population. 
Therefore, the p53 Arg72Pro polymorphism may be used 
as a stratification marker in screening individuals at a 
high risk of breast cancer. In summary, the findings of the 
present study indicate that the p53 codon 72 
polymorphism may be a genetic predisposing factor for 
breast adenocarcinomas, and p53 Arg 72 protein may be 
correlated with possible increased risk of this kind of 
cancers in central part of Iran. 
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